<DOC>
	<DOC>NCT00264953</DOC>
	<brief_summary>This study is designed to (1) compare the efficacy of the BEACOPP regimen with that of ABVD as a 4-cycle chemotherapy combined with an involved field irradiation and (2) to define the optimum radiation dose comparing of 30 to 20 Gy in the same context.</brief_summary>
	<brief_title>HD11 for Intermediate Stages</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Hodgkin´s lymphoma (histologically proven) CS (PS) IA, IB, IIA, with one of the risk factors ad CS (PS) IIB only with risk factor c or d 1. bulky mediastinal mass (&gt; 1/3 maximum transverse thorax diameter) 2. extranodal involvement 3. ESR &gt; 50 (A), &gt; 30 (Bsymptoms) 4. 3 or more lymph node areas involved written informaed consent Leukocytes &lt;3000/microl Platelets &lt;100000/microl Hodgkin´s Disease as "composite lymphoma" Activity index (WHO) &lt; grade 2</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Hodgkin´s lymphoma</keyword>
	<keyword>intermediate stages</keyword>
</DOC>